-
Naftifine HCl in Cell Viability Assays
2026-09-11
This evidence-based guide explains how Naftifine HCl, SKU B1984, can be incorporated into cell viability, proliferation, and cytotoxicity workflows without confusing antifungal mechanism with mammalian-cell toxicity. It covers solvent control, assay optimization, interpretation of muscle-cell experiments, and practical supplier qualification.
-
U 46619 for Platelet and Vascular Assays
2026-09-11
U 46619 is a concentration-tunable TP-receptor agonist for separating early platelet signaling from later secretion, aggregation, and fibrinogen-receptor responses. This workflow-focused guide explains assay setup, vascular applications, troubleshooting, and practical interpretation of concentration-dependent phenotypes.
-
Iguratimod Prodrug Rewires RA Synovial Crosstalk
2026-09-10
A 2026 Journal of Orthopaedic Translation study identifies TYK2 JH2-dependent STAT1 signaling as a mechanistic link between invasive rheumatoid arthritis fibroblast-like synoviocytes and macrophage inflammation. It also presents AD811, an iguratimod prodrug that preserves experimental efficacy while improving pharmacokinetic behavior, offering a useful framework for studying synovial cell-cell signaling and drug design.
-
Estrogen Receptor–Autophagy Axis in Perimenopause
2026-09-10
This reference study integrates NHANES population data, a perimenopausal mouse model, network pharmacology, and inhibitor-based validation to examine how declining estradiol relates to cardiometabolic and renal vulnerability. Its main contribution is functional evidence that receptor-dependent autophagy helps mediate estrogen-associated protection against fibrosis in the heart, aorta, and kidneys.
-
TMRE Mitochondrial Membrane Potential Assay Guide
2026-09-09
Learn how the TMRE mitochondrial membrane potential assay kit converts ΔΨm changes into mechanistic insight rather than treating fluorescence as a simple apoptosis label. This guide connects TMRE measurements with sodium-driven mitochondrial energy failure, assay controls, interpretation, and scalable experimental design.
-
Balsalazide Disodium: Applied Research Workflows
2026-09-09
Balsalazide Disodium Dihydrate combines water-compatible handling with microbiota-dependent activation, making it useful for colon-targeted inflammation research, radiolabeling development, and inflammatory bowel disease models. This guide translates its 5-aminosalicylic acid prodrug biology into practical protocols, controls, and troubleshooting decisions.
-
GSTA1 and α-Amanitin Hepatotoxicity
2026-09-08
The reference study identifies GSTA1 as an unexpected driver of α-amanitin liver injury rather than a purely protective detoxification enzyme. Using mouse toxicology, HUH7-cell experiments, integrated transcriptomics and metabolomics, molecular docking, DARTS, and genetic perturbation, the authors connect NRF2-associated GSTA1 upregulation with glutathione depletion, reactive oxygen species accumulation, and hepatocyte damage.
-
JHU-083 for Glutaminase Pathway Research
2026-09-07
JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor designed for selective glutaminase pathway interrogation in cerebral CD11b cells. This guide connects experimental cerebral malaria research with practical glutamate, redox, multi-omics, and troubleshooting workflows while clearly separating established evidence from exploratory applications.
-
G007-LK Tankyrase 1/2 Inhibitor Guide
2026-09-07
A scenario-driven guide to using G007-LK tankyrase 1/2 inhibitor in viability, proliferation, and cytotoxicity workflows. It explains how SKU B5830 supports mechanistic Wnt, β-catenin, and Hippo-pathway studies while addressing dosing, formulation, interpretation, and vendor-selection decisions.
-
ML385: Practical NRF2 Inhibition Workflows
2026-09-05
ML385 provides a practical pharmacological handle for testing NRF2-dependent antioxidant signaling, therapeutic resistance, and redox-sensitive phenotypes. This workflow connects non-small cell lung cancer research with emerging NRF2 studies in inflammation and osteolysis while emphasizing controls, target engagement, and troubleshooting.
-
VE-821 ATR Kinase Inhibitor Workflow Guide
2026-09-04
VE-821 enables selective ATR checkpoint inhibition for DNA damage response studies, radiosensitization assays, and chemotherapy sensitization workflows. This guide connects practical assay design with the DNMT1-centered HBoV1 findings while clearly separating established product applications from exploratory cross-domain hypotheses.
-
Streptavidin-HyperFluor 647: Assay Design
2026-09-04
Streptavidin-HyperFluor 647 supports sensitive red-fluorescent detection of biotinylated targets. This article presents a readout-first framework for choosing it across microscopy, flow cytometry, FRET, and proximity-labeling workflows.
-
Machine Learning Prediction of mRNA Vaccine LNPs
2026-09-04
The reference study developed a LightGBM model that predicted lipid nanoparticle formulations for mRNA vaccines with an R² above 0.87 from 325 formulation records. By combining machine learning, mouse validation, and molecular dynamics, it showed how computational screening can prioritize ionizable lipids and formulation conditions while also identifying structural features relevant to performance.
-
GPNMB Model Predicts ESCC Immunotherapy Response
2026-09-03
This reference study links circulating soluble GPNMB to a CAF–epithelial niche, SOX2 activation, CD8+ T-cell exhaustion, and resistance to PD-1 blockade in esophageal squamous cell carcinoma. Its multimodal model combines plasma, spatial, and clinicopathologic information to improve response and survival prediction, while offering a mechanistic framework for biomarker-guided immunotherapy research.
-
Vasopressin Analogues: Structure, Signaling, and Translation
2026-09-02
Glavaš and colleagues review how vasopressin structure, receptor signaling, and peptide engineering create analogues with distinct antidiuretic, vasoconstrictor, and therapeutic profiles. The article is particularly useful for interpreting lypressin, desmopressin, and terlipressin across endocrine, cardiovascular, and emerging antiviral research while distinguishing established applications from preliminary hypotheses.